Ethinylestradiol/levonorgestrel continuous - Pfizer

Drug Profile

Ethinylestradiol/levonorgestrel continuous - Pfizer

Alternative Names: EE/Levo continuous - Pfizer; EE/LNG continuous - Pfizer; Levo/EE continuous - Pfizer; Levonorgestrel/ethinlyestradiol continuous - Pfizer; Librel®; LNG/EE continuous - Pfizer; Lybrel

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pfizer; Wyeth
  • Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy
  • Discontinued Premenstrual dysphoric disorder; Premenstrual syndrome

Most Recent Events

  • 07 Jun 2011 Generic equivalent approved in USA for Contraception/Pregnancy (Prevention)
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 02 Jul 2007 Launched for Contraception/Pregnancy (Prevention) in USA (PO) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top